In an interview with CNBC-TV18, Nav Rattan Munjal, VC & MD, IndSwift Laboratories spoke on the company's business plans.
Below is a verbatim transcript. Also watch the accompanying video.
Q: Most of your revenues actually come from in terms of export markets from semi regulated markets and Europe. What is your expectation from US and Japan going forward? It comprises of small part of your revenues right now? How do you expect to scale it up?
A: I think the revenue will grow both from the off market or non-regulated market and USA, Europe. US market and regulated market of Europe and Japan is a boost to our company both in terms of value and both in terms of the reputation. Recently we have filed two DMFs in the US. These markets are basically from a 5-year point of view. If we start today then we will acquire the valuations after 4 to 5 years.
Q: In particular about Japan what is your expectation?
A: In Japan we have got PMDA approval very recently and now we have filed 7 DMFs in the Japan market. Right now the revenue from the Japan market is not very good looking compared to our overall sale but going forward by 2014-2015 we expect to bring it to 10% of our total revenue.
